Shares of the genetic-testing company 23andMe (NASDAQ: ME) gained another 16% through Thursday's close this week, according to data from S&P Global Market Intelligence . The biotech's stock is now up by more than 34% over the past two weeks.
23andMe's shares have been ripping higher ever since EMJ Capital founder Eric Jackson identified the biotech as a top pick during an interview on CNBC on Oct. 15 . While Jackson appeared bullish on the company's well-established health and ancestry-data business, he singled out 23andMe's fledgling therapeutics platform as perhaps the biggest reason to buy shares.
Image source: Getty Images.
For further details see:
Why 23andMe Stock Has Jumped 16% So Far This Week